Literature DB >> 8165645

Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study.

G J Miller1, Y Stirling, M P Esnouf, J Heinrich, J van de Loo, J Kienast, K K Wu, J H Morrissey, T W Meade, J C Martin.   

Abstract

Plasma from healthy individuals, pregnant women and patients on warfarin were distributed to 3 laboratories supporting major cardiovascular surveys (Northwick Park, Muenster and Houston) for assay of factor VII coagulant activity (VIIc) with their own bio-assays. The mean VIIc in 147 samples agreed to within 1% of standard in Northwick Park and Houston, but was 14% of standard lower in Muenster owing to its more potent standard. In samples with an increased VIIc the Northwick Park assay gave a higher result than the other assays owing to its increased responsiveness to activated factor VII (VIIa). Thus when VIIa concentrations were determined directly with a clotting assay which utilises a soluble recombinant tissue factor, the increase in VIIc with increase in VIIa was considerably greater with the Northwick Park assay than the Muenster assay. This feature of the Northwick Park assay was traced to the virtual absence of protein C in its substrate plasma. Factor Va appears rate-limiting for the coagulant expression of VIIa in test plasma. If the thrombotic response to release of tissue factor is determined by the circulating concentration of VIIa, then the Northwick Park factor VII bio-assay may be preferable to other bio-assays currently employed to estimate risk of acute coronary events.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165645

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.

Authors:  G Ken-Dror; F Drenos; S E Humphries; P J Talmud; A D Hingorani; M Kivimäki; M Kumari; K A Bauer; J H Morrissey; H A Ireland
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

2.  Effects of different protein sources on plasminogen inhibitor-1 and factor VII coagulant activity added to a fat-rich meal in type 2 diabetes.

Authors:  Lene S Mortensen; Claus Thomsen; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2010-11-10

3.  Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children.

Authors:  Peter H Whincup; Julie A Gilg; Olia Papacosta; Carol Seymour; George J Miller; K G M M Alberti; Derek G Cook
Journal:  BMJ       Date:  2002-03-16

4.  A randomized trial to evaluate the effectiveness of dietary advice by practice nurses in lowering diet-related coronary heart disease risk.

Authors:  P Roderick; V Ruddock; P Hunt; G Miller
Journal:  Br J Gen Pract       Date:  1997-01       Impact factor: 5.386

5.  Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.

Authors:  N C Olson; L M Raffield; L A Lange; E M Lange; W T Longstreth; G Chauhan; S Debette; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2017-12-08       Impact factor: 5.824

6.  Influence of stearic acid on postprandial lipemia and hemostatic function.

Authors:  Thomas A B Sanders; Sarah E E Berry
Journal:  Lipids       Date:  2005-12       Impact factor: 1.880

7.  Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial.

Authors:  Susan A Jebb; Julie A Lovegrove; Bruce A Griffin; Gary S Frost; Carmel S Moore; Mark D Chatfield; Les J Bluck; Christine M Williams; Thomas Ab Sanders
Journal:  Am J Clin Nutr       Date:  2010-08-25       Impact factor: 7.045

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.